Skip to main content
OpenTrials
Completed

NCT Number: NCT00808730

Role of Mitochondria in Non Severe Asthma

Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodelling. Bronchial remodelling is an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It can appear very early in the evolution of the disease and involves an increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis in severe asthma (T. Trian et al. J Exp Med 2007). The objective of this study is to investigate the role of smooth muscle cell mitochondria in non severe asthma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Airway Remodeling Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Bordeaux, Hôpital Haut-Lévêque

Pessac, 33604, France

About this study

Bronchial remodelling mainly involves an increased mass of bronchial smooth muscle (BSM), which is related with an increase proliferation of BSM cells. Recently, using BSM cells obtained from severe asthmatics, we have demonstrated that such an increase proliferation was induced by an activation cascade involving an abnormal calcium entry, and the subsequent activation of Calmodulin-kinase IV, PGC-1alpha, NRF-1 and mt-TFA leading to an increase mitochondrial biogenesis (T. Trian et al, J Exp Med 2007). The objective of this study is to investigate the role of BSM cell mitochondria in non severe asthma.

For this purpose, 30 non severe asthmatic adult patients (>18 yr) will be prospectively recruited from the "CHU de Bordeaux" according to the Global Initiative for Asthma (GINA) guidelines. Inclusion visit will include written informed consent, asthma control questionnaire, clinical examination, lung function testing (i.e. arterial gas, exhaled NO, plethysmography), prick tests, chest X Ray and blood sample for total IgE levels. Bronchial specimens will be obtained from all subjects by fiberoptic bronchoscopy. BSM remodelling will be evaluated by morphological analysis. Patients will be divided into 2 groups according to the presence or the absence of BSM remodelling. Using BSM cell culture, the role of mitochondria will be analyzed by electronic microscopy, confocal microscopy, immunoblotting, RT-PCR and oxygraphy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged more than 18 years
  • Diagnosis of intermittent asthma, mild persistent asthma or moderate persistent according to ATS criteria
  • Forced expiratory volume in one second > 60% predicted
  • Written informed consent

Exclusion criteria

  • Smoker or former smoker (tobacco or cannabis)
  • Adults protected by law
  • Subjects not affiliated with social security
  • Subjects during exclusion relative to another protocol or for which the annual maximum allowance of 3800 euros has been reached
  • Subject with any co-morbidity (except chronic rhinitis, chronic sinusitis nasal polyps or gastro-oesophageal reflux)
  • Asthma exacerbation within 6 weeks before enrolment
  • Infections of the upper airway within 3 months before enrolment
  • Chronic viral infections (hepatitis, HIV)
  • Pregnancy or breastfeeding
  • Contraindications to bronchoscopy

Treatment and study plan

fiberoptic fibroscopy

Procedure

Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment

Primary outcomes

  1. BSM mitochondrial biogenesis assessed by the number of mitochondrial sections using electron microscopy, the porin content using western blot, and mitochondrial oxygen consumption evaluated by oxygraphy.

    Time frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment

Secondary outcomes

  1. BSM remodelling assessed by optic microscopy and immunohistochemistry (using anti-alpha smooth muscle actin antibody).

    Time frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment

  2. Transcription factors involved in mitochondrial biogenesis assessed by quantitative RT-PCR and western blot.

    Time frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Role of Mitochondria in Human Bronchial Smooth Muscle Remodeling in Non Severe Asthma

Acronym: MITASTHME

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Dec 16, 2008
Registry last updated
Feb 17, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.